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Pre-clinical study of induced pluripotent stem
cell-derived dopaminergic progenitor cells
for Parkinson’s disease
Daisuke Doi 1, Hiroaki Magotani1,2, Tetsuhiro Kikuchi 1, Megumi Ikeda 1,3, Satoe Hiramatsu1,3,
Kenji Yoshida1,3, Naoki Amano4, Masaki Nomura4, Masafumi Umekage4, Asuka Morizane1 &
Jun Takahashi 1✉
Induced pluripotent stem cell (iPSC)-derived dopaminergic (DA) neurons are an expected
source for cell-based therapies for Parkinson’s disease (PD). The regulatory criteria for the
clinical application of these therapies, however, have not been established. Here we show the
results of our pre-clinical study, in which we evaluate the safety and efficacy of dopaminergic
progenitors (DAPs) derived from a clinical-grade human iPSC line. We confirm the char-
acteristics of DAPs by in vitro analyses. We also verify that the DAP population include no
residual undifferentiated iPSCs or early neural stem cells and have no genetic aberration in
cancer-related genes. Furthermore, in vivo studies using immunodeficient mice reveal no
tumorigenicity or toxicity of the cells. When the DAPs are transplanted into the striatum of 6-
OHDA-lesioned rats, the animals show behavioral improvement. Based on these results, we
started a clinical trial to treat PD patients in 2018.
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The discovery that the transplantation of fetal midbraintissues can restore neurological symptoms of Parkinson’sdisease (PD) patients1–4 has stimulated interest in cell
therapies for the disease. Human pluripotent stem cells (PSCs),
such as embryonic stem cells (ESCs) and induced PSCs (iPSCs),
are sources for a stable supply of cells for the therapy5. Culture
protocols that induce authentic midbrain dopaminergic (DA)
neurons from human PSCs have already been established by
several research groups, and the DA neurons have been proven
safe and effective in rodent6,7 and primate8 PD models. These
results suggest that PSC-derived DA neurons can contribute to
the treatment of PD. However, the use of PSCs for cell-based
therapies is such a new challenge that regulatory rules are not
universally standardized. Indeed, each country has its own reg-
ulations and different criteria for clinical application. Therefore,
to develop a global standard cell-based therapy for PD, it is
important to share the results of pre-clinical studies and the
outcomes of clinical trials9.
Currently, two clinical trials using human ESCs are ongoing in
Australia (NCT02452723) and China (NCT03119636), and their
pre-clinical studies are reported10,11. We recently started a clinical
trial (JMA-IIA00384, UMIN000033564) in Japan to treat PD
patients by using iPSC-derived DA progenitors (DAPs). Because
in these therapies the grafted cells survive and function as DA
neurons for a long time (possibly until the patient dies), they
must undergo more intensive risk management compared to
other clinical trials using mesenchymal stem cells12, in which the
grafted cells function to provide neurotrophic support or
immunomodulation but not as DA neurons, and do not survive
long. Since 2015, we have continued discussion with the Japanese
regulatory agency, Pharmaceuticals and Medical Devices Agency
(PMDA), about details of the pre-clinical study. In this report, we
show that the DAPs have no tumorigenicity or toxicity and that
they improve the abnormal behavior of 6-hydroxydopamine (6-
OHDA)-lesioned rats. Thus, we confirm the safety and efficacy of
iPSC-derived DAPs for clinical trials.
Results
Manufacturing iPSC-derived DAPs under good manufacturing
practice (GMP) conditions. As a starting material, we used a
human iPSC line (QHJI01s04) derived from the peripheral blood
cells of a human leukocyte antigen (HLA)-homozygous healthy
volunteer13,14 and established for clinical application at the
Center for iPS Cell Research and Application, Kyoto University,
Japan. Then, we established a clonal master cell bank, MCB003,
for our project. We have preserved the iPSCs in hundreds of
frozen vials as one lot. To treat a patient, we thaw one of the vials,
differentiate the cells into DAPs, and transplant them without
freezing. In this pre-clinical study, we used multiple vials to
confirm reproducibility of the results.
We modified our culture protocol to induce DAPs from human
iPSCs8,15 to meet the GMP-grade culture condition (Fig. 1a–d,
Supplementary Table 1). Briefly, human iPSCs (MCB003) were
seeded onto 6-well plates coated with laminin 511-E8 fragment
and cultured for 12 days, and then CORIN+16 cells were isolated
by fluorescence-activated cell sorting (FACS). The sorted cells
were cultured in 96-well plates as cell aggregates until day 30 and
then used for the transplantation. In this culture condition, all
reagents including an anti-CORIN antibody were at GMP grade.
A clinical-grade cell sorter with a disposable fluid tube was
equipped to mitigate the risk of cross-contamination.
Characterization of iPSCs (MCB003) in vitro. In the process of
inducing DAPs, quality control check points were placed at the
stage of MCB003, pre- and post-FACS sorted cells, and the final
product (Fig. 1e). The quality standards of MCB003 include the
morphology of the colonies, the expression of pluripotent mar-
kers such as TRA-1–60, TRA-2–49, and SSEA-4, and sterility. We
confirmed that almost all cells expressed pluripotent cell markers
(Supplementary Table 2).
Characterization of the final product in vitro. We conducted
the DAP induction process in 25 randomly chosen vials from
MCB003 (one time for each vial). Before sorting on day 12, the
percentages of TRA-1–60+ and CORIN+ cells were 0.0% (n=
24) and 31.4 ± 12.7% (n= 25), respectively. After sorting, the
percentage of CORIN+ cells were 93.2 ± 2.1% (n= 25), con-
firming purity (Table 1, Supplementary Fig. 1a, b). The in-process
testing for the manufacturing of DAPs is described in Supple-
mentary Table 3.
The quality standards of the final product were determined to
confirm that the cells were mainly composed of DAPs and
included no undifferentiated cells. For this purpose, the
expression of markers for DAPs (FOXA2 and TUJ1), iPSCs
(OCT3/4= POU5F1, LIN28, and TRA-2–49), and proliferating
early neural progenitors (SOX1, PAX6, and KI67) were examined
by flow cytometry and quantitative reverse transcription PCR
(RT-qPCR). Flow cytometry on day 26 revealed that the
percentage of DAPs (FOXA2+TUJ1+) was 92.3 ± 4.0% (n= 25;
Table 1 and Supplementary Fig. 1c, d). Immunostaining also
showed that most cells expressed DAP markers such as LMX1A
and FOXA2 (Fig. 1f), and a smaller population expressed more
mature DA markers such as NURR1 and TH (Fig. 1g).
Regarding undifferentiated cells, immunostaining showed that
day-26 spheres did not contain iPSCs (OCT3/4 and NANOG;
Fig. 1h) nor early neural progenitors (SOX1 and PAX6; Fig. 1i).
Flow cytometry revealed that OCT3/4+TRA-2–49+ double-
positive cells were not detected. The same flow cytometry analysis
of DAP samples spiked with 0.1% iPSCs or SOX1+PAX6+
double-positive cells confirmed that the detection levels meet the
test specification (Table 1, Supplementary Fig. 1e, f). In addition,
RT-qPCR analysis showed that the expression levels of POU5F1
(OCT3/4) and LIN28 were 0.08 ± 0.15% and 0.14 ± 0.13% (n= 25
each) those of undifferentiated iPSCs, respectively (Table 1,
Supplementary Fig. 1g, h).
To further confirm that there were no residual iPSCs, day-26
spheres were cultured in a condition suitable for iPSCs for
2 weeks. In this experiment, we mixed 0.001 to 1.0% of iPSCs
with 2 × 105 dissociated cells from the day-26 spheres and found
that even 0.001% was enough to form visible iPSC colonies.
Importantly, day-26 spheres without mixture did not show any
colony formation (Supplementary Fig. 1i). Taken together, these
results indicated that the final product contained no or minimal
(<0.001%) undifferentiated iPSCs.
N\ext, we examined if the DAPs could differentiate into
functional DA neurons. To evaluate the production of dopamine,
day-26 spheres were cultured until day 56 on L-ornithine/laminin/
fibronectin-coated plates, and dopamine release in response to
high KCl stimulation was measured by liquid chromatography
with tandem mass spectrometry (LC-MS/MS) (n= 5, Fig. 1j).
The amount of dopamine was 3.30 ± 2.72 pmol μg−1 DNA in
the cultured media, 0.47 ± 0.45 pmol μg−1 DNA in low KCl, and
1.46 ± 0.65 pmol μg−1 DNA in high KCl. Upon electrophysiolo-
gical analyses, we found 67% of examined neurons showed
spontaneous action potentials (Fig. 1k, l) and 89% of neurons
showed induced action potentials (n= 18, Fig. 1m). The resting
membrane potential was −49 ± 15mV.
Genomic, epigenetic, and single-cell analyses. The results above
suggest that there is no tumorigenic component in the final
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product. However, genomic and epigenetic changes in the cells
may affect cell behavior after transplantation. To examine this
possibility, genomic and epigenetic stability during the differ-
entiation was examined, and the final products were subjected to
tumorigenicity studies. We repeated DAP induction six times and
compared the results of whole-genome sequencing (WGS) and
whole-exome sequencing (WES) obtained from original periph-
eral blood cells, undifferentiated iPSCs, and differentiated cells on
days 12 and 26.
We extensively investigated mutations in the 686 cancer-
related genes listed in the Catalog of Somatic Mutations In
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included 242 genes in Shibata’s gene list (a cancer-related gene list
made by the PMDA; Supplementary Table 4) and mutations
annotated with the Human Gene Mutation Database (HGMD)
PRO database (2016.4). No genomic mutations were detected by
WGS (Table 2). WES revealed single-nucleotide variants (SNVs)
in three genes, but this discovery was not consistently observed
and thought to be a false positive after considering the results of
the amplicon sequencing (Supplementary Tables 5, 6). In
addition, there were no residual plasmids or copy number
variations (CNVs) in all samples tested.
Regarding epigenetic modifications, we examined the methyla-
tion ratio at the transcriptional start site of 73 cancer-related
genes. Our final products showed lower methylation levels than
those of tissues with brain malignant tumor glioblastoma
multiforme and similar levels with normal cells and fetal ventral
mesencephalon (Fig. 2a and Supplementary Fig. 2).
To examine the variation of the gene expressions among the six
independent preparations, we performed a single-cell RT-qPCR
analysis. In each cell preparation, iPSCs on day 0, CORIN+ cells
on day 12, and the final products on day 26 showed similar
expression patterns in t-distributed stochastic neighbor embed-
ding (tSNE) plots (Fig. 2b). In addition, there was no difference in
the expression of genes related to DA differentiation (Fig. 2c,
Supplementary Data 1). These results support the reproducibility
of the cell manufacturing process.
Tumorigenicity, toxicity, and biodistribution studies. The same
final products used for the genomic and epigenetic analyses were
subjected to tumorigenicity studies. We repeated DAP induction
six times, and each DAP population was injected into the right
striatum, which is the same target used in the clinical trial, of
immunodeficient NOG (NOD.Cg-PrkdcscidIl2rgtm1Sug/ShiJic)
mice. In this study, the toxicity and biodistribution of the cells
were also examined. After discussion with the PMDA, we
observed the animals as long as possible, namely for a life-long
period. Initially, we grafted day-30 spheres (2 × 105 cells per
mouse, maximum dose) into 80 (males: 40, females: 40) and 50
mice (males: 25, females: 25) as the cell product-transplanted
group and saline-injected control group (Supplementary Table 7),
respectively, and observed the groups until the number of sur-
viving male or female mice was 30 (transplantation group) or 20
(control group). At 52 weeks after transplantation (59–60 weeks
old), the number of male mice in the control group was 19, at
which point we stopped the observation. At this time, 28 males
and 27 females survived in the transplantation group, and 19
males and 22 females survived in the control group. A survival
curve of the animals showed no significant difference between
groups (log-rank test, p= 0.3208, Fig. 3a). No changes were
attributable to the transplantation in the mice’s general condi-
tions, body weight, food consumption, pharmacological condi-
tions (modified Irwin test), ophthalmological findings, urinalysis,
hematology and blood chemistry data, necropsy, or organ weight.
Hematoxylin–eosin (H–E) staining of 5-μm-thick brain slices
revealed no proliferative or malignant findings, and immunos-
taining for tyrosine hydroxylase showed that DA neurons had
survived (Fig. 3b–e). In 23 (12 males and 11 females) of the 55
mice in the transplantation group, tubular cell clusters were
found in the grafts and expressed pan-cytokeratin and
Fig. 1 Characterization of human iPSC-derived dopaminergic progenitors. a An overview of the pre-clinical study. b–d Representative pictures of b iPSCs,
c day-12 cultured cells before sorting, and d day-26 cultured aggregate spheres. Bars= 200 μm (n= 25 independent experiments). e Scheme of the cell
production process in the GMP facility. f–i Immunofluorescence images of day-26 aggregate spheres sliced. Bars= 100 μm (n= 25 independent
experiments). j The results of the LC-MS/MS analysis of the dopamine release by day-56 cultured cells under high potassium stimulation. Values are the
mean ± SD (n= 5 independent experiments). k Representative image of whole-cell patch-clamp recordings. The patched cell was stained with Biocytin
Alexa Fluor™ 488. Bar= 100 μm. l Representative current-clamp recording of spontaneous action potentials. m Representative current-clamp recording of
action potentials induced by brief current pulses. k, l n= 2 independent experiments, the total number of cells= 18. PCS primary cell stock, SCS secondary
cell stock, MCB master cell bank, QC quality control.
Table 1 Characterization of the final product.





TRA-1–60 <1% (pre-sort) 0.0% (n= 24)
CORIN >10% (pre-sort) 31.35 ± 12.72%
>90% (post-sort) 93.15 ± 2.127%
Morphology Microscopic observation Sphere shaped, no foreign body Complied
Viability Flow cytometry: Cell count >90% 97.48 ± 1.608%
DAP markers Flow cytometry: FOXA2/TUJ1 >80% 92.29 ± 3.964%
Undifferentiated markers qPCR: POU5F1 and LIN28 <1% compared to undifferentiated cells POU5F1: 0.08 ± 0.15%




Early neural markers Flow cytometry: SOX1/PAX6 <0.1% <0.1%
Sterility JP17 (membrane filter) Negative Negative
Mycoplasma JP17 (PCR) Negative Negative
Endotoxin JP17 (LAL turbidimetry test) ≤1 EUmL−1 Not analyzed
Residual plasmids qPCR: Transfected genes Not detected Not detected (n= 6)
CNV SNP array No abnormalities compared to
undifferentiated iPSCs in:








LAL, limulus amebocyte lysate.
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transthyretin (TTR), suggesting that these cells have character-
istics of choroid plexus epithelial cells (Supplementary Fig. 3a, b).
The cell clusters were very small (<0.5 mm in diameter), not
frequent (mean 1.4 clusters per graft), and not proliferating (no
expression of KI67). In addition, they showed no effect on the
survival or neurite extension of surrounding DA neurons. These
results verified no tumorigenicity of the final products. Toxicity
and biodistribution were also investigated using the same animals
(see “Methods”), no abnormal findings were observed in the
toxicity study, and grafted human cells (KU80+) were found only
in the brain and not in systemic organs.
Teratoma formation assay in subcutaneous space. We further
examined the existence of residual iPSCs in the final products by
injecting day-30 spheres into the subcutaneous space of NOG
mice with Matrigel, which is reported to be the most sensitive
method to detect teratoma formation by residual undifferentiated
iPSCs17. As a spike control, 0.001–10% of undifferentiated iPSCs
(MCB003) were mixed into the day-30 spheres. As a positive
control, another cell line of iPSCs (201B7, established by a ret-
roviral vector with c-Myc18) and HeLa cells were used. When
600,000 HeLa cells or 201B7 cells were injected, subcutaneous
tumors became detectable at around 10 weeks. In contrast, there
was no tumor formation for 26 weeks in the DAP group, DAP
with spiked MCB003 group, or even MCB003 group (Fig. 3f).
Histological analysis revealed that KU80+ human cells survived
in the DAP groups. On the other hand, no KU80+ cells were
detected in the MCB group, suggesting that undifferentiated
MCB003 cells cannot survive in the subcutaneous space
(Fig. 3g–o). Similarly, MCB003 cells did not form any tumors in
the mouse striatum, while 201B7 cells formed large teratomas
(Supplementary Fig. 3c). When MCB003 cells were injected into
the testes of NOG mice, however, they formed typical teratomas,
indicating that they were viable and pluripotent (Supplementary
Fig. 3d). These results suggested that undifferentiated MCB003
cells do not remain in day-30 spheres, and that even if they did,
the risk of teratoma formation is negligible.
Efficacy study using 6-OHDA-lesioned rats and MPTP-treated
monkeys. To confirm the efficacy of clinical-grade iPSC
(MCB003)-derived DAPs, day-30 spheres (4 × 105 cells per rat)
were transplanted into the striatum of 6-OHDA-lesioned nude
rats (n= 8, vehicle control, n= 6), and methamphetamine-
induced rotation was evaluated every 4 weeks. In the trans-
planted group, rotational asymmetry was reversed to normal
levels by 16 weeks, while the control group showed no change in
rotational behavior (Fig. 4a, two-way analysis of variance
(ANOVA), Sidak’s multiple comparison test, p value: ***=
0.0002; ****<0.0001). Immunohistochemistry showed 2835 ±
2534 TH+FOXA2+ DA neurons survived and extended axons in
the striatum (Fig. 4b–h).
For the clinical trial, we have developed a long-thin needle that
is attachable to a stereotaxic frame. To examine the usability of
the needle, MCB003-derived day-30 spheres (1.5–2.0 million cells
per monkey) were transplanted into the left putamen of MPTP
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-treated monkeys
(n= 3). Histological analysis 6 months after the transplantation
revealed that the grafted DA neurons survived without any
adverse effects, including hemorrhage or inflammation
(Fig. 4i–n). The results of the in vivo pre-clinical studies are
summarized in Supplementary Table 8.
Discussion
For the clinical application of a cell-based therapy, a 2 × 2 matrix
(Safety, Efficacy × Cellular and Non-cellular components; Sup-
plementary Table 9) is recommended for quality control of the
final product. In our case, the active cellular component is iPSC-
derived DAPs. We confirmed that 92.3% of the total cells are
FOXA2+TUJ1+ DAPs on culture day 26. We also confirmed
that some of the survived human cells in rat were positive for
GFAP, which suggests glial progenitors were included in the
grafted cells with DAPs. The DAPs became mature DA neurons
that produced dopamine and improved the abnormal behaviors
of 6-OHDA-lesioned rats. Two previous clinical trials for PD
using PSCs have transplanted ESC-derived neural progenitor cells
(NCT02452723) and ESC-derived DA neurons (NCT03119636).
These pre-clinical studies are summarized in Table 3.
There are three cellular components that should not be con-
tained in the final product. The first is undifferentiated iPSCs, and
we confirmed their absence by four methods in vitro. The second
is early neural stem cells. Previously, we found that SOX1+
PAX6+ cells exist in the early stage of differentiation and that
these cells form rosettes and proliferate in the brain19. The
expression of CORIN, however, is never common with SOX1 or
PAX6 expression. As a result, we can eliminate SOX1+PAX6+
cells by sorting CORIN+ cells. The third is transformed cells. The
genomic instability of iPSCs and their derivatives may lead to
tumorigenicity20,21. However, the need for genomic analysis is
controversial, because genomic abnormalities do not always cause
tumors. In addition, there is no standard gene list for which we
should investigate. In this situation, we decided to investigate the
genes listed in COSMIC Census and the cancer-related gene list
made by the PMDA as well as familial disease-related genes listed
in a HGMD PRO database. We performed WGS and WES of
both iPSCs and the final products, but detected no aberrations in
these genes. Epigenomic changes in iPSCs are another possible












Day 0 None 0 0 0 None
Day 12 NA 0 0 0 None
Day 26 None 0 0 0 None
CT1DAP-161011
Day 0 None 0 0 0 None
Day 12 None 0 0 0 None
Day 26 None 0 0 0 None
CT1DAP-161018
Day 0 None 0 0 0 None
Day 12 None 0 0 0 None
Day 26 None 0 0 0 None
CT1DAP-161025
Day 0 None 0 0 0 None
Day 12 None 0 BARD1 0 None
Day 26 None 0 0 0 None
CT1DAP-161028
Day 0 None 0 0 0 None
Day 12 None 0 MUC4 0 None
Day 26 None 0 MUC4 0 None
CT1DAP-161101
Day 0 None 0 NCKIPSD 0 None
Day 12 None 0 0 0 None
Day 26 None 0 0 0 None
NA, not analyzed.
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cause of tumorigenicity, because iPSCs are reported to have
higher variability in DNA methylation22. From our results of a
methylation array, iPSCs and the final products were not hyper-
methylated compared with malignant brain tumor tissue and
instead showed a methylation rate consistent with normal cells.
Tumorigenicity studies in vivo are also not standardized. In
previous pre-clinical studies, the observation periods in nude rats
and SCID (severe combined immunodeficiency) mice were
9 months (Table 3)10,11,23. In the case of spinal cord injury, ESC-
derived oligodendrocyte progenitors (two million cells) were
injected into the spinal cord of SCID mice, and the histological
analysis was performed 12 months later24. In the present study,
we used NOG mice, in which not only T cell and B cell activities
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WNT5A ZBTB16 Preparation









Fig. 2 Genome/epigenome analysis and single-cell-based gene expression analysis. a Representative results of the methylation array analysis of the
DAPs (cell preparation: CT1DAP-161011) used in the tumorigenicity study. b A t-SNE plot of the single-cell data of the six lots tested in the tumorigenicity
study. Each lot contains undifferentiated cells (day 0), intermediates (day 12), and the final product (day 26). c Violin plots of the expression pattern in
DAPs from the six tested lots in the tumorigenicity study by single-cell RT-qPCR. GBM glioblastoma multiforme, VM ventral mesencephalon.
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response25. The observation period was 52 weeks, which
approximates the mouse lifespan. Because we found no pro-
liferating cells or abnormal findings in the grafts, 52 weeks (or
12 months) seem to be long enough for tumorigenicity study. Of
note, before starting the pre-clinical study, we consulted the
PMDA about the study design. The PMDA requested we use
NOG mice, which is the least immunogenic animal model, is
sensitive to tumor development17,26, and offers a long observation
period. The PMDA also requested we evaluate at least 10 animals
per group in the histological analysis. Major discussion points





Media male (n = 25)
Media female (n = 25)
Cells male (n = 40)
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Regarding non-cellular components, we need to use clinical- or
GMP-grade materials and reagents. We have made a GMP-grade
anti-CORIN antibody and carefully confirmed that its remnant
on cells was negligible. Regarding donor eligibility for iPSCs, a
medical interview and blood exam for contamination were con-
ducted. For other materials, γ-ray irradiation and viral elimina-
tion were applied to meet Japanese standards for biological raw
materials. In addition, following guidelines of the International
Council for Harmonization of Technical Requirements for
Pharmaceuticals for Human Use (ICH) Q5A, we confirmed that
the clinical-grade iPSCs (MCB003) were not contaminated with
pathogenic viruses (Supplementary Table 11).
Unexpectedly, choroid plexus epithelia-like cells were observed
in 23 of 55 mice with transplantation of the final product. In all
cases, the cell clusters were microscopic (<0.5 mm), not frequent,
not proliferating, and asymptomatic. Because bone morphoge-
netic protein (BMP) signaling is essential for developing choroid
plexus tissue27, we modified our differentiation protocol to extend
the period of the BMP inhibition (Supplementary Fig. 4a).
Accordingly, we successfully reduced the expression of TTR, a
marker for the choroid plexus, in the final product, without any
changes of other DA markers (Supplementary Fig. 4b, c).
Transplantation to nude rat resulted in TTR+ cells appearing in
two out of seven rats without the BMP inhibitor, but in no rats
out of six rats with the BMP inhibitor (Supplementary Fig. 4d).
We also confirmed that extension of the BMP inhibition can
reduce the risk of inducing TTR+ epithelium-like cells in
the brain.
In conclusion, the safety and efficacy of clinical-grade cell
products were confirmed in this study. Based on these results, we
received approval to start a clinical trial for PD from the PMDA
and the institutional regulatory board of Kyoto University. The
trial is ongoing.
Methods
Establishment of iPSC stock and manufacturing of DAPs. This study was
approved by the ethics committee of Kyoto University Hospital and Center for iPS
cell Research and Application (CiRA), Kyoto University, Kyoto, Japan. After
informed consent was obtained from an HLA-homozygous volunteer donor, an iPSC
stock for clinical use was established by reprogramming the donor’s peripheral blood
with episomal plasmid vectors expressing OCT3/4, SOX2, KLF4, L-MYC, LIN28,
mp53DD, and EBNA1 at a cell processing center (Facility for iPS Cell Therapy,
CiRA). The peripheral blood cells were isolated by using Ficoll-Paque PREMIUM
(GE Healthcare), and 1.2 × 107 mononuclear cells were cultivated with StemFit AK03
without solution C (contains basic fibroblast growth factor) media (Ajinomoto) with
50 ngmL−1 interleukin-6 (IL-6), 50 ngmL−1 stem cell factor, 10 ngmL−1 throm-
bopoietin, 20 ngmL−1 Flt-3 ligand, 20 ngmL−1 IL-3, and 10 ngmL−1 granulocyte
colony-stimulating factor (all WAKO) in four wells of a 24-well plate (3 × 106 cells
per well). After 7 days of cultivation, the vectors were induced in 5 × 106 dissociated
cells by a Nucleofector 4D electroporation system (Lonza), and the cells were
replated on laminin 511-E8 fragment (iMatrix, Nippi)-coated 6-well plates (1.67 ×
105 cells per well) in the same media as the mononuclear cells. One milliliter per well
of StemFit AK03 media (Ajinomoto) was added 3, 5, and 7 days after the induction,
and 9 days onward StemFit AK03 media were exchanged every 3 days. After 3 weeks
of cultivation, single-cell-derived colonies became visible, and we picked up 15 of
them manually. Each colony was dissociated with TrypLE Select CTS (Thermo
Fisher), and all the cells were transferred to an iMatrix-coated 12-well plate and
defined as passage 1 (P1). The P1 cells were passaged at 1.4 × 103 cells cm−2 every
8–12 days, and 30 vials of a primary cell stock (PCS) were frozen at P4. Two out of
fifteen PCS clones were identified as iPSCs by ESC-like morphology, the absence of
residual plasmids, confirmation of a normal karyotype, the expression of surface
markers of undifferentiated iPSCs, and efficient neural differentiation. We selected
the clones with the best efficiency for DA differentiation for the transplantation
experiments. In order to confirm that the iPSCs were plasmid free by a longer
culture, one vial of the PCS was thawed (P5) and expanded to 70 vials of secondary
cell stock (SCS, P9). After thawing the SCS, we confirmed that there was no residual
plasmids (tested at P9, P12, and P19), that they expressed undifferentiated markers
(TRA-1–60, SSEA-4, and TRA-2–49; tested at P15), and had normal karyotypes (46,
XY; tested at P12 and P13). One vial of the SCS was thawed and passaged two times,
and then 384 frozen vials of MCB (P12) were stored. All freezing procedures were
performed by using a programmed freezer. iPSCs were dispensed at 2 × 105 or 5 ×
105 cells per tube in 200 or 500 μL of Stem Cell Banker GMP grade (TAKARA Bio,
CB045), frozen to −80 °C at −1 °Cmin−1, and stored in the gas phase of a liquid
nitrogen tank.
Frozen MCB was differentiated after two passages of maintenance culture on
iMatrix in StemFit AK03 medium was conducted. To manufacture the DAPs, the
iPSCs were dissociated into single cells after 10-min incubation with 0.5× TrypLE
select CTS (Thermo Fisher) and plated onto iMatrix-coated 6-well plates at a
density of 5 × 106 cells well−1 in differentiation media containing Glasgow’s
minimum essential medium (Thermo Fisher) supplemented with 8% γ-ray-
irradiated knockout serum replacement (Thermo Fisher), 0.1 mM MEM
(minimum essential medium) non-essential amino acids (Thermo Fisher), 1 mM
sodium pyruvate (Sigma-Aldrich), and 0.1 mM 2-mercaptoethanol. A ROCK
inhibitor, Y-27632 (final 10 μM), was added when the cells were dissociated, and
the day of dissociation was defined as differentiation day 0. The media were
changed daily, and 100 nM LDN193189 was added from days 0 to 12, 500 nM A83-
01 was added from days 0 to 6, 100 ng mL−1 fibroblast growth factor 8, and 2 μM
purmorphamine were added from days 1 to 6, and 3 μM CHIR99021 was added
from days 3 to 12. All materials and reagents used in this study are listed in
Supplementary Table 12. On differentiation days 12 and 13, the cells were
dissociated using 0.5× TrypLE select CTS, stained by phycoerythrin-conjugated
anti-CORIN antibody (final concentration 100 ng mL−1, Sumitomo Dainippon
Pharma) for 20 min, and suspended with the sorting buffer containing phosphate-
buffered saline (PBS)(−), 2% γ-ray-irradiated fetal bovine serum, 20 mM D-
glucose, 80 μg mL−1 gentamicin, and 10 μM Y-27632. Data analysis and cell sorting
were performed with a FACSAria III or an Influx cell sorter (BD Biosciences). A
100-μm ceramic nozzle with a sheath pressure of 20 or 26 psi and an acquisition
rate of ~5000 events s−1 were used for the cell sorting. The positive gate was set so
that <0.1% of cells were positive in unstained samples or samples stained by an
isotype control antibody. Sorted CORIN+ cells were plated onto PrimeSurface®
U-shaped 96-well plates (Sumitomo Bakelite) at a density of 2–3 × 104 cells well−1
to make aggregate spheres in neural differentiation media containing Neurobasal
medium with γ-ray-irradiated B27 supplement (without Vitamin A), 2 mM L-
glutamine, 10 ng mL−1 glial cell-derived neurotrophic factor, 200 mM ascorbic
acid, 20 ng mL−1 brain-derived neurotrophic factor, and 400 μM dibutyryl cAMP.
Thirty micromolars of Y-27632 and 80 μg mL−1 gentamicin were added at the
initial plating after sorting, and the media were changed every 3 days until
shipment or evaluation. The cell number of each aggregate sphere was calculated
by the result of the flow cytometric analysis at day 26, and the number of spheres
for animal transplantation was estimated by the cell number. At differentiation day
30, the aggregate spheres were collected in custom-made cell containers (JMS),
washed with saline four times, and stored at 5 °C until shipment. A step-by-step
protocol describing the DAP differentiation can be found at Protocol Exchange28.
Flow cytometry. Flow cytometric analysis was performed using cells on differ-
entiation days 12 and 26. On differentiation day 12, pre-sorted cells were stained by
fluorescein isothiocyanate (FITC)-conjugated anti-TRA-1–60 antibody (1:5, BD
#560380) for 20 min, followed by dead-cell staining by 7-aminoactinomycin D
(1:100, BD #559925). On differentiation day 26, cultured spheres were dissociated
to single cells by Neuron Dissociation Solutions S (FUJIFILM Wako Pure Chemical
Corporation) and stained by the LIVE/DEAD® Fixable Dead Cell Stain Kit
(Thermo Fisher) and FITC-conjugated anti-TRA-2–49 antibody (Merk-Millipore),
followed by fixation by 4% paraformaldehyde for 30 min. After fixation, the cells
were permeabilized by Perm/Wash buffer (BD Biosciences #554723) for 30 min,
stained by antibodies for intracellular staining (Supplementary Table 13), and
rinsed with Perm/Wash buffer. Stained samples were analyzed by Canto II or
FACSAria III flow cytometer. The compensation setting of each fluorescence was
Fig. 3 Histological analysis of the tumorigenicity study. a Survival curves of NOG mice tested in the tumorigenicity study. b–e Representative images of
brain sections of the NOG mice used in the tumorigenicity study. b–d H–E staining (c is a magnification of b, and d a magnification of c) and e
immunohistochemistry for tyrosine hydroxylase counter stained by hematoxylin. Bars in b= 1 mm, c= 500 μm, and d, e= 100 μm. Number of cell
preparation= 6, and number of animals= 80 (transplantation) and 50 (control). f Time course of the subcutaneous mass volume of NOG mice used in
the teratoma formation assay. Dots are mean values of each group. g–o Representative images of grafts in the subcutaneous space of NOG mice injected
with HeLa cells (g, number of animals= 8), 201B7 iPSCs (h, i, number of animals= 6), MCB003 iPSCs (j–l, number of animals= 20), and MCB003 DAPs
(m–o, number of animals= 21). i is a magnification of h, k, l are magnifications of j, and n, o are magnifications of m. l, o Staining by KU80. Bars in g, h, j,
m= 1 mm, in i, k, l, n, o= 100 μm. g–i Number of cell preparation= 1 and j–o number of cell preparations= 7.
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adjusted by using the AbC Anti-Mouse Bead Kit and ArC Amine Reactive Com-
pensation Kit (Thermo Fisher).
Quantitative reverse transcription with polymerase chain reaction (qRT-
PCR). The total RNA fraction was extracted by NucleoSpin RNA XS (Takara Bio)
and reverse transcribed by the SuperScript III First-Strand Synthesis System
(Qiagen) or PrimeScript™ RT reagent Kit with gDNA Eraser (Takara Bio).
Quantitative PCR was carried out with TaqMan™ Gene Expression Master Mix
(Thermo Fisher) according to the manufacturer’s instructions. The expression
levels of the genes were normalized to GAPDH using the standard curve method.
Probes and primers are as follows:







Immunostaining. For in vitro studies, spheres were fixed with 4% paraformalde-
hyde and sliced at 10 μm thickness by using a cryostat (CM-1850, Leica Biosys-
tems). Double- or triple-labeled immunostaining was performed after
permeabilization, antigen retrieval if needed, and blocking with 0.1% Triton X-100
and 2% skim milk. The stained samples were visualized by using a fluorescence
microscope (BZ-X710; Keyence) and a confocal laser microscope (Fluoview
FV1000D; Olympus). The primary and secondary antibodies are listed in Sup-
plementary Table 13.
Single-cell analysis. Single-cell complementary DNA (cDNA) preparation and
gene expression analysis were performed following the manufacturer’s protocol. A
cell suspension of iPSCs (day 0), intermediate cells after sorting (days 12 and 13),
or DAPs (day 26) at 300 cells μL−1 were used. C1 Suspension Reagent (Fluidigm)
was added to the cell suspension at a ratio of 40%. Six microliters of cell suspension
mix were loaded on a C1 Single-Cell AutoPrep IFC microfluidic chip (Fluidigm)
designed for cells 10–17 μm in size, and the chip was then processed on a Fluidigm
C1 instrument using the “STA: Cell Load (1862×)” script. Live and single cells were
confirmed under an inverted microscope. Then, the “STA: Preamp (1862×)” script
was executed, which includes lysis, reverse transcription, and 18 cycles of PCR.
When the run had finished, the amplified cDNA was harvested in a total of 28 μL
C1 Harvesting Reagent. The amplified cDNA from single cells and DNA primers
were then loaded onto a Biomark chip (Fluidigm) for expression profiling with a
panel of qRT-PCR assays (Biomark HD, Fluidigm). The chip was then loaded onto
Biomark HD to analyze gene expression levels. The expression data were processed
and analyzed using the Singular Analysis Toolset version 3.6.2 (Fluidigm). The
gene expression profiles of the analyzed cells were visualized using tSNE. A
spectrum of gene expressions was visualized by violin plots. The sequences of the
DNA primers are listed in Supplementary Table 14.
Electrophysiological analysis. To analyze the electrophysiological properties of
cultured neurons, 42-day cultured spheres were attached on L-ornithine/laminin/
fibronectin-coated glass coverslips. After 14 days, whole-cell patch-clamp record-
ings were performed. Neurons on the surface of the spheres were chosen for the
examination. The spheres were maintained in a physiological saline solution of
the following composition: 125 mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 1 mMMgCl2,
26 mM NaHCO3, 1.25 mM NaH2PO4, and 17 mM glucose. Patch pipettes were
made from borosilicate glass capillaries (1B150F-4; World Precision Instruments)
and had a resistance of 3–4MΩ when filled with an internal solution composed of
140 mM KCl, 10 mM HEPES, and 0.2 mM EGTA (pH 7.3). To visualize the pat-
ched cells, 100 µM Biocytin Alexa Fluor™ 488 was added to the internal solution.
Recordings with a voltage clamp and current clamp were made with a patch-clamp
amplifier (Axopatch 200B; Molecular Devices). The giga-seal resistances were in
the range of 10–20 GΩ. The current signals from the amplifier were filtered at
1 kHz and stored and analyzed on a 64-bit computer (Cooler Master). All
experiments were performed at room temperature.
Dopamine measurement by LC-MS/MS. Spheres on differentiation day 28 were
replated onto L-ornithine/laminin/fibronectin-coated 12-well plates with neural
differentiation medium and cultured for 28 days. The medium was replaced 24 h
before the measurements. On culture day 56, the cells were washed twice with low
KCl solution (20 mM HEPES-NaOH, pH 7.4, 140 mM NaCl, 4.7 mM KCl, 2.5 mM
CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, and 11 mM glucose) and incubated in
low KCl solution for 15 min. The medium was subsequently replaced with 1 mL of
high KCl solution (20 mM HEPES-NaOH, pH 7.4, 85 mM NaCl, 60 mM KCl,
2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, and 11 mM glucose) for 15 min.
The solution was then collected, and the concentration of dopamine was deter-
mined by LC-MS/MS (Sumika Chemical Analysis). Plated cells were harvested in
PBS and sonicated. DNA concentration of the cell lysate was measured using the
Quant-iT™ dsDNA Assay Kit (Thermo Fisher) and used for compensation of the
DA concentration. Data were calculated from five independent experiments.
Extended culture on iPSC maintenance condition. Cells on culture day 26 or 30
were dissociated to single cells and replated onto iMatrix-coated 24-well plates at 2 ×
105 cells per sample with StemFit AK03N iPSC maintenance media. Undifferentiated
iPSCs were dissociated as well, and iPSCs were spiked into 2 × 105 DAPs at 0.001–1%.
After 14 days, the cells were stained by alkaline phosphatase using the AP Staining
Kit™ (System Biosciences), and the colonies were counted manually.
Genomic/epigenomic analysis and testing residual plasmids. WGS and WES
libraries were prepared from 200 and 100 ng of genomic DNA as starting materials
following the manufacturer’s instructions, respectively. For WGS, libraries were made
with the KAPA Hyper Prep Kit (Kapa Biosystems) without PCR. For WES, adapter-
ligated libraries were prepared with the KAPA Hyper Prep Kit, and sequencing
libraries were generated with the SeqCap EZ Human Exome Library v3.0 (Roche).
Cluster generation was done with the HiSeq PE Cluster Kit v4-cBot (illumina) using
illumina cBot. Sequencing was performed with the HiSeq SBS Kit v4 using HiSeq2500
and 2 × 126 PE mode. After generating FASTQ files by bcl2fastq v2.17.1.14 (illumina)
and performing adapter trimming by cutadapt 1.1029, FASTQ files were mapped to
the reference human genome (hg19) by BWA MEM30 (ver. 0.7.15) (for Genomon2,
–T 0 option was used), and duplicated reads were removed by NovoSort (Novocraft)
(ver. 1.03.09). To call SNV/Indels in test samples compared with donor cells, bam files
were analyzed by Genomon31 (ver. 1.0.1) with Fisher’s exact test (P < 0.001) and
Genomon232 (ver. 2.3.0) with EB call (P(Fisher) < 0.1 and P(EB call) < 0.001 for
WGS, and P(Fisher) < 0.1 and P(EB call) < 0.0001 for WES), followed by adapting the
custom filters. Mutations were annotated by ANNOVAR33 (2016Feb01) and
restricted on CDS and splicing regions. To further extract potentially pathogenic
mutations, we excluded synonymous mutations and focused on mutations annotated
with HGMD34, COSMIC Cancer Gene Census35 (ver. 83), and Shibata’s gene list
[http://www.pmda.go.jp/files/000152599.pdf]. WGS data were utilized for calling
CNV using VarScan236 (2.4.2) in combination with Otsu’s threshold method37 and
Delly38 (0.7.3) by comparing test samples with donor cells, followed by curating the
called CNVs manually. In addition to utilizing WGS data, CNVs were called using an
SNP genotyping array. Genomic DNA (starting from 200 ng) was hybridized onto the
HumanOmniExpress24 v1.2 DNA Analysis Kit (illumina), and intensities were
scanned by iScan (illumina) following the manufacturer’s protocol. After exporting a
final report using GenomeStudio (V2011.1) (illumina), CNV analysis was performed
using PennCNV39 (1.0.3), Mosaic Alteration Detection-MAD40 (1.0.1), and GWAS
tools41 (1.16.1), followed by comparing test samples with original cells and curating
the called CNVs manually.
For the methylation analysis, the bisulfite conversion of 500 ng genomic DNA
was performed using the EZ DNA Methylation Kit (Zymo Research), followed by
methylation profiling using the Infinium MethylationEPIC BeadChip Kit
(Illumina) according to the manufacturer’s protocols. After exporting the
methylation data by using GenomeStudio (V2011.1) and normalizing the beta
values by using BMIQ42, we calculated the beta values of 73 genomic blocks at the
transcription start sites of cancer-related genes as described previously43 and
visualized them using R (https://www.R-project.org) with ggplot244. As a reference,
53 methylation datasets of normal tissues (in GSE31848) and 11 methylation
datasets of glioblastoma multiforme (downloaded from TCGA, Sentrix_ID:
9976861010) were also visualized.
Residual plasmids were tested by quantitative PCR with TaqMan™ Gene
Expression Master Mix (Thermo Fisher). Quantitative PCR was done to amplify
exogenous genes (KLF4, SOX2, L-MYC, LIN28, Trp53DD, OCT3/4, and EBNA1) in
Fig. 4 Results of the efficacy study. a Rotational assays of methamphetamine-injected rats. Two-way ANOVA and Sidak’s multiple comparison test,
adjusted p value: ***= 0.0002 and ****<0.0001. b–e Representative images of the brain of a rat (number of animals= 8 for cell transplantation and 6 for
saline injection) after transplantation and stained for b TH, c HNA (green) and TH (magenta), d TH (green) and FOXA2 (magenta), and e HNA (green)
and GFAP (magenta). Bars in b= 1 mm, c= 50 μm, and d, e= 100 μm. R= right side of brain. f–h Representative images of the brain of a rat after
transplantation and DAB stained for TH. g, hMagnified images of the boxes in f. Bars in f= 1 mm and g, h= 100 μm. i–k A magnetic resonance imaging (i)
of the transplanted monkey and representative images (j, k) of the graft stained for TH. Arrowhead in i shows the grafts. Bars in j= 1 mm and k= 50 μm.
l–n Representative H–E staining of the brain of a monkey after transplantation (m is a magnification of l, and n is a magnification of m). Bars in l= 5 mm,
m= 1 mm, n= 200 μm. b–n Number of cell preparations= 2 and number of animals= 3.
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the plasmid using iPSC genome DNA and real-time PCR Thermal Cyclers
(StepOnePlus; Thermo Fisher). The DNA quantity was normalized to the copy
number of endogenous FBX15. The DNA genomes of more than 25,000 cells were
used as the template for the PCRs based on the copy number of endogenous
FBX15. The probes and primers are as follows:
KLF4 probe, forward and reverse: Hs00358836_m1 (Thermo Fisher),



















Amplicon sequencing. Primers for amplicon sequencing were designed with primer.
py (Amelieff) and ApE (2.0.54) [https://jorgensen.biology.utah.edu/wayned/ape/]. For
the multiplex PCR reaction, 10 ng of genomic DNA and 200mM of primer mix
(primers with KAPA HiFi HotStart ReadyMix (Roche) and 5% dimethyl sulfoxide)
were mixed and PCR reaction was performed with the following condition: the initial
denature was done at 95 °C for 5min, followed by 35 cycles of denature at 98 °C
for 20 s, annealing at 60 °C for 15 s, extension at 72 °C for 30 s, and final extension at
72 °C for 1 min. After purifying amplicon with 1.8x Agencourt AMPure XP Beads
(Beckman Coulter), we made sequencing library with KAPA Hyper Prep Kit (Roche).
Library was sequenced with MiSeq (Illumina) using MiSeq Reagents Kit v2 according
to the manufacturer’s instruction. The sequenced reads were aligned to the reference
genome by BWA MEM (Ver. 0.7.15) and alternative allele frequencies at the targets
were calculated by samtools (ver. 0.1.19)45.
Animal studies. All animals were cared for and handled according to the
Guidelines for Animal Experiments of Kyoto University and that of Shin Nippon
Biomedical Laboratories (Kagoshima, Japan), and all animal experiments were
certified by an ethics committee at Kyoto University and Shin Nippon Biomedical
Laboratories.
Tumorigenicity/toxicity/biodistribution study. Seven–eight-week-old male and
female NOG mice (CLEA Japan) were used for the transplantation. Cells were
transplanted stereotactically, and the coordinates of the striatum were calculated with
reference to the bregma: anterior (A), +0.5mm; lateral (L), −2.0 mm; ventral (V),
−3.0mm; and tooth bar (TB), 0mm. Two hundred thousand cells in 0.6–2.8 μL were
injected through a 24G needle (Hamilton 7105KH). Fifty-two weeks after the
injection, the mice were euthanized with isoflurane and pentobarbital and perfused
transcardially with PBS. The brains were immersion fixed by 10% formalin, paraffin
embedded, and sliced with a microtome at 5 μm thickness throughout the graft. One
of every 10 sections was used for H–E staining, and the other sections were used for
immunohistochemisty. Other systemic organs (Supplementary Table 15) were also
immersion fixed by 10% formalin and paraffin embedded and sliced with a micro-
tome at 5 μm thickness. One of the sections was used for H–E staining, and the others
were used for immunohistochemistry by anti-TH, anti-KU80, anti-KI67, anti-cyto-
keratin, and anti-TTR antibodies (Supplementary Table 13).
Toxicity and biodistribution analyses were combined with a tumorigenicity test
of the brain injection in NOG mice. The test items evaluated are listed in
Supplementary Table 15.
Teratoma formation study (subcutaneous and testis injection). Five–nine-
week-old male NOG mice were used. Two hundred fifty or 500 μL of dissociated
single-cell solutions containing 6 × 105 cells mixed with ice-cold Matrigel (BD
356237) were injected by using a 22 G needle (Hamilton 750N) into the sub-
cutaneous space of the upper back. The DAPs were spiked with 0.001–10% (6 ×
100–6 × 104) undifferentiated iPSCs by the stepwise dilution method, and the cell
concentration was confirmed to be within ±15% of the target concentration. The
subcutaneous tumor size was measured by calipers, and the tumor volume was
calculated via the following formula:
Volume ðmm3Þ ¼ Long diameter ´ ðshort diameterÞ2=2:
After 26 weeks of observation, the subcutaneous tissue was fixed by 10% formalin,
and all tissues were paraffin embedded and sliced at 5 μm thickness for staining.
Animals in the positive control group (HeLa cells and iPSC line 201B7) were observed
for 16 weeks or until the subcutaneous tumor volume was over 1500mm3.
Ten microliters (6 × 105 cells) of dissociated cells were injected into the right
testis with a 22sG needle (Hamilton 702N). After 16 weeks of observation, the
testes were extracted and fixed by FSA solution (formalin–sucrose–acetic acid). All
fixed tissues were paraffin embedded and sliced at 5 μm thickness for staining.
Efficacy study. Transplantation of human iPSC-DAPs in 6-OHDA-lesioned rats:
Adult (8–9-week-old) male nude rats (F344/NJcl-rnu/rnu, CLEA, Japan) were used
for the lesioning. 6-OHDA injection was performed into the medial forebrain
bundle, and only rats that showed more than six rotations per minute were used in
the cell transplantation experiments. Cell transplantation was performed with the
stereotactic injection of 4 × 105 cells (200,000 cells μL−1) by using a 22 G needle
(Hamilton 7105KH) into the right striatum (from the bregma: A, +1.0 mm; L,
−3.0 mm; V, −5.0 and −4.0 mm; and TB, 0 mm).
Behavioural analysis: Methamphetamine-induced rotation behavior was
evaluated before and every 4 weeks after the transplantation. The rotation was
recorded for 90 min after the intraperitoneal injection of methamphetamine (2.5
mg kg−1, Sumitomo Dainippon Pharma). The rotation number was counted by the
RotoRat software version 2.01 (Med Associates, Inc., Vermont, USA).
Immunostaining: Twenty weeks after the transplantation, the rats were
euthanized with isoflurane and pentobarbital and perfused with Ca2+, Mg2+-free
PBS, and 4% paraformaldehyde. After post fixation for 1 day and immersion in
30% sucrose solution, the brains were sliced at 35 μm thickness for staining.
Immunostaining was performed as in the in vitro studies. For 3,3′-
diaminobenzidine (DAB) staining, sections were treated with 0.3% hydrogen
peroxide in PBS with Tween 20 (PBST), incubated with primary antibodies,
incubated with biotinylated antibodies against rabbit IgG (1:2000; Vector
Laboratories), and then incubated with avidin peroxidase (1:4000; Vectastain ABC
Elite Kit, Vector Laboratories). Signal detection was done by using DAB (Dojindo
Laboratories) with nickel ammonium.
Transplantation of hiPSC-DAP in MPTP monkey by using custom-made
needles: Adult male cynomolgus monkeys were supplied by Shin Nippon Biomedical
Laboratories. Hemi-parkinsonian models were made by the intra-arterial injection of
MPTP hydrochloride via the left carotid artery. A total of 1.5–2.0 × 106 cells per
animal (four tracts, three deposits per tract) were transplanted into the left putamen of
the monkeys with a customized surgical needle for the cell transplantation (TOP
Corporation, Japan). After surgery, the monkeys were given antibiotics for 3 days and
an intramuscular immunosuppressant (FK506, 0.05 mg kg−1, Astellas) daily from one
day before the transplantation to the day of sacrifice. The monkeys were subjected to
magnetic resonance imaging scanning before and after the transplantation and finally
sacrificed. Detailed descriptions of the monkey experiments are reported elsewhere8.
Statistical analysis. Statistical analyses were performed by using the GraphPad
Prism 7 software (GraphPad Software). Data from the survival curve of the
transplanted animals were analyzed by the log-rank test (Fig. 3a), and the beha-
vioral data were analyzed by a two-way ANOVA with Sidak’s multiple compar-
isons test (Fig. 4a). P values < 0.05 were considered significant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Most of the data that support the findings of this study are available within the article and
its Supplementary Information files or from the corresponding author upon reasonable
request. Some of the data are not publicly available due to them containing information
that could compromise donor privacy.
The datasets used in this study are as follows:




Shibata’s gene list: http://www.pmda.go.jp/files/000152599.pdf
refGene, genomicSuperDups, snp131, esp6500siv2_all, 1000g2015aug_all were
downloaded through ANNOVAR as humandb 20160720: https://doc-openbio.
readthedocs.io/projects/annovar/en/latest/.
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